EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens

Francisco Ibarra iD, Evan Cheng iD, Benjamin Falkenstein

Pharmacy · 19.08.2026 · 14 (5) · 121

DOI: 10.3390/pharmacy14050121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacy, online erschienen am 19.08.2026. Verfasst von Francisco Ibarra und 2 weiteren Autor:innen. Beteiligte Einrichtung: Community Regional Medical Center, Department of Pharmacy Services, 2823 Fresno St., Fresno, CA 93715, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The optimal fixed-dose strategy for managing warfarin-associated hemorrhages remains unknown and few studies have evaluated the use of Factor VIII Inhibitor Bypass Activity (FEIBA). This retrospective cohort study’s primary efficacy outcome was the percentage of patients who achieved a post-FEIBA INR ≤ 1.5 following receipt of the old and new dosing regimens. In the old group patients received 500 or 1000 units for an INR < 5 or ≥5, respectively. In the new group patients received 1000, 1500, or 2000 units for an INR < 5, 5–9.9, or ≥10, respectively. Eighteen patients were included in each group. The median (IQR) pre-FEIBA INR in the old and new groups was 6.1 (3.1–12.9) and 5.3 (3.4–13.0), respectively [difference: −0.8 (95 CI%, −7.2 to 6.5)]. The median (IQR) post-FEIBA INR in the old and new groups was 1.6 (1.4–2.1) and 1.4 (1.2–1.5), respectively [difference: −0.2 (95% CI: −0.6 to 0.0)]. A post-FEIBA INR ≤ 1.5 was achieved in 14 (78%) patients in the new group and 9 (50%) patients in the old group (relative risk: 1.56; 95% CI, 0.91 to 2.7; p = 0.16). The post-FEIBA INR values in the patients who did not achieve a post-FEIBA INR ≤ 1.5 in the new group were 1.6, 1.6, 1.8, and 2.4. Among patients with a baseline INR ≥ 10, significantly more patients in the new group achieved a post-FEIBA INR ≤ 1.5 compared to the old group (86% vs. 17%, respectively). These findings suggest that the new FEIBA dosing regimen may improve INR reversal compared with the previous regimen, particularly among patients with a baseline INR ≥ 10, but larger studies are needed to confirm this observation.

Schlagwörter

Stichwörter der Autor:innen

FEIBAPCCanticoagulanthemorrhageprothrombin complex concentratewarfarin reversal

Autor:innen und Institutionen

  • Community Regional Medical Center, Department of Pharmacy Services, 2823 Fresno St., Fresno, CA 93715, USA.
  • College of Osteopathic Medicine, California Health Sciences University, 2500 Alluvial Ave, Clovis, CA 93611, USA.
  • Department of Emergency Medicine, University of California San Francisco at Fresno, 155 N Fresno St., Fresno, CA 93701, USA.

ORCID-Profile: Francisco Ibarra, Evan Cheng

Zitieren

APA

Ibarra, F., Cheng, E., & Falkenstein, B. (2026). A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens. Pharmacy, 14(5), 121. https://doi.org/10.3390/pharmacy14050121

Vancouver

Ibarra F, Cheng E, Falkenstein B. A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens. Pharmacy. 2026;14(5):121. doi:10.3390/pharmacy14050121

BibTeX
@article{Ibarra2026,
  author = {Ibarra, Francisco and Cheng, Evan and Falkenstein, Benjamin},
  title = {A Novel Fixed-Dose Activated Prothrombin Complex Concentrate Regimen for Warfarin-Associated Hemorrhages: A Retrospective Cohort Comparison of Two Regimens},
  journal = {Pharmacy},
  year = {2026},
  volume = {14},
  number = {5},
  pages = {121},
  doi = {10.3390/pharmacy14050121}
}
Kostenlos starten →